Sitagliptin and Cardiovascular Outcomes in Type 2 Diabetes

N Engl J Med. 2015 Dec 17;373(25):2479. doi: 10.1056/NEJMc1510995.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Cardiovascular Diseases / complications*
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Humans
  • Hypoglycemic Agents / adverse effects*
  • Pyrazines / adverse effects*
  • Triazoles / adverse effects*

Substances

  • Hypoglycemic Agents
  • Pyrazines
  • Triazoles